Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Frontiers in Medicine

Early-onset low rectal adenocarcinoma with a pMMR/MSS phenotype in a patient with an analytically confirmed germline pathogenic PMS2 variant: a case report

  1. 1Department of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China
  2. 2Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China

Abstract

Mismatch repair (MMR) protein immunohistochemistry (IHC) and microsatellite instability (MSI) testing are central to colorectal cancer treatment stratification and hereditary-risk assessment, but a pMMR/MSS tumour phenotype does not exclude a germline predisposition in selected patients. We report a 41-year-old woman with low rectal adenocarcinoma whose pretreatment biopsy and resection specimen retained MLH1, PMS2, MSH2 and MSH6 expression and whose tumour was microsatellite stable (MSS) with low tumour mutational burden (TMB-L). Tumour-tissue sequencing initially identified the PMS2 frameshift variant NM_000535.7:c.1577del (p.Asp526AlafsTer69; GRCh37/hg19 chr7:6026819delT). A subsequent orthogonal assay using PMS2-specific three-step nested genomic PCR, TA cloning and Sanger sequencing of peripheral-blood DNA confirmed that the variant mapped to PMS2 and supported its germline origin; the clinical laboratory classified the variant as pathogenic using an ACMG/AMP-based interpretation. No dedicated analyses of tumoural PMS2 somatic second-hit events, loss of heterozygosity, copy-number alterations or promoter methylation were performed; therefore, biallelic PMS2 inactivation was not established. Postoperative circulating tumour DNA molecular residual disease was positive, and a left supraclavicular lymph-node biopsy subsequently confirmed metastatic adenocarcinoma consistent with colorectal origin. This case illustrates that pMMR/MSS findings should not be used in isolation to exclude hereditary risk in patients with early-onset disease or other clinical indications for germline assessment. These findings support selective germline assessment in patients with early-onset or otherwise high-risk pMMR/MSS colorectal cancer, but do not justify universal testing or establish that the tumour was caused by PMS2-associated Lynch syndrome.

Related

  1. Incidental MSH6 Germline Pathogenic Variant Identified through Tumor-only Comprehensive Genomic Profiling in a Patient with Small Cell Lung Cancer
    Hideto Ishimoto, Mikako Miyata, Chiyomi Otsuka +5
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  2. Case Report: Early-onset bilateral and multifocal clear cell renal cell carcinoma in a carrier of the germline likely pathogenic CHEK2 splice-region variant NM_007194.4:c.846 + 4_846 + 7del
    Ewa Czukiewska, Jacek Kiś, Dominika Szczęśniak +7
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  3. Colon cancer in a patient with a mosaic monoallelic germline pathogenic NF1 gene variant.
    Feras Alsabagh, Karam M Chaaban, Marlene Girardo +5
    Exploration of neurosciencePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Double heterozygous pathogenic germline APC and MSH2 variants in a 16-year-old female diagnosed with colorectal cancer
    Elena Maccaroni, Riccardo Bacalini, Alessia Lancianese +20
    Familial CancerPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  5. Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants
    P. V. B. D. Cerqueira, F. A. B. Campos, S. M. Caputo +15
    Breast Cancer Research and TreatmentPeer-reviewedCC BY 4.0Full textOncologyPMC
BibTeX
@article{li2026earlyonset,
  title = {{Early-onset low rectal adenocarcinoma with a pMMR/MSS phenotype in a patient with an analytically confirmed germline pathogenic PMS2 variant: a case report}},
  author = {Ying Li and Heming Ma and Fuxue Huang and Zhuo Wang and Meichen Gu and Pengyu Chang},
  journal = {Frontiers in Medicine},
  year = {2026},
  month = oct,
  doi = {10.3389/fmed.2026.1945282},
  url = {https://doi.org/10.3389/fmed.2026.1945282},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Early-onset low rectal adenocarcinoma with a pMMR/MSS phenotype in a patient with an analytically confirmed germline pathogenic PMS2 variant: a case report
AU  - Ying Li
AU  - Heming Ma
AU  - Fuxue Huang
AU  - Zhuo Wang
AU  - Meichen Gu
AU  - Pengyu Chang
PY  - 2026
DA  - 2026/10/30
JO  - Frontiers in Medicine
DO  - 10.3389/fmed.2026.1945282
UR  - https://doi.org/10.3389/fmed.2026.1945282
AB  - Mismatch repair (MMR) protein immunohistochemistry (IHC) and microsatellite instability (MSI) testing are central to colorectal cancer treatment stratification and hereditary-risk assessment, but a pMMR/MSS tumour phenotype does not exclude a germline predisposition in selected patients. We report a 41-year-old woman with low rectal adenocarcinoma whose pretreatment biopsy and resection specimen retained MLH1, PMS2, MSH2 and MSH6 expression and whose tumour was microsatellite stable (MSS) with low tumour mutational burden (TMB-L). Tumour-tissue sequencing initially identified the PMS2 frameshift variant NM_000535.7:c.1577del (p.Asp526AlafsTer69; GRCh37/hg19 chr7:6026819delT). A subsequent orthogonal assay using PMS2-specific three-step nested genomic PCR, TA cloning and Sanger sequencing of peripheral-blood DNA confirmed that the variant mapped to PMS2 and supported its germline origin; the clinical laboratory classified the variant as pathogenic using an ACMG/AMP-based interpretation. No dedicated analyses of tumoural PMS2 somatic second-hit events, loss of heterozygosity, copy-number alterations or promoter methylation were performed; therefore, biallelic PMS2 inactivation was not established. Postoperative circulating tumour DNA molecular residual disease was positive, and a left supraclavicular lymph-node biopsy subsequently confirmed metastatic adenocarcinoma consistent with colorectal origin. This case illustrates that pMMR/MSS findings should not be used in isolation to exclude hereditary risk in patients with early-onset disease or other clinical indications for germline assessment. These findings support selective germline assessment in patients with early-onset or otherwise high-risk pMMR/MSS colorectal cancer, but do not justify universal testing or establish that the tumour was caused by PMS2-associated Lynch syndrome.
SN  - 2296-858X
ER  -